Neurosurgery Drugs Market Drivers, Challenges, Growth Opportunities, and Forecasts through 2025

0
133

Transparency Market Research has published a new report, titled “Neurosurgery Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025.” The report states that, the global neurosurgery drugs market is chiefly flourishing on account of drawing incidences of neurological disorders, especially among the geriatric population. It is therefore obvious, that stupendous increase in the geriatric population worldwide is inadvertently behind the rising demand for neurosurgery drugs. The market also benefits from global campaigns against epilepsy which advocates the use of phenobarbital. Such campaigns are increasing the health promotions and awareness in emerging nations and this is also favouring the growth of the neurosurgery drugs market.

As per the World Health Organization, by 2030, over a 103 million disability-adjusted life-years is the figure which is predicted due to neurological diseases. This increase in the incidences of neurological diseases when subsequently bolster the demand for neurological surgeries and is subsequently the demand for neurosurgery drugs.

However, there are a few issues with neurosurgery drugs which are anticipated to restrict the growth of this market. There are long-term side effects of several neurosurgery drugs and therefore neurologist are reducing their use. As neurosurgery drugs have narrow therapeutic index coupled with zero order kinetics, these drugs are one of the most complicated antiepileptic drugs to use. Neurosurgery drugs also bring about significant bi-directional drug interactions and they may even cause difficulty in coordinating movements, cause headaches, confusion, dizziness, nausea, and drowsiness. Apart from all these factors, neurosurgery can cause abnormalities in the baby if a pregnant woman were to take these drugs. All these factors are threatening the growth of the global neurosurgery drugs market.

Download Brochure of Reporthttps://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37808

On the basis of disease type the neurosurgery drugs market is segmented into cardiac glycoside intoxication, status epilepticus, neuropathic pain, seizures, and cardiac arrhythmias. On the basis of drug class, this market is segmented into Group 1 antiarrhythmics and hydantion anticonvulsants. On the basis of distribution channel, the global neurosurgery drugs market is segmented into hospital pharmacies, online pharmacies, and a retail pharmacies. The online pharmacies is emerging as a fast drawing distribution channel for neurosurgery drugs.

On the basis of geography, it is anticipated that North America will continue to lead in the nearest surgery drugs market on account of the escalating geriatric population as well as continuously increasing research and development activities to what’s the development of efficient neurosurgery drugs. The growing stress levels as well as rising incidences of drug addiction for pain relief are some of the factors behind the growth of the European neurosurgery drugs market. Moderate growth is also forecasted within the Asia-Pacific region during the period from 2017 to 2025 on account of the technological advancements as well as levels. Health promotions within the Middle East and Africa and Latin America regions are expected to give the neurosurgery market a significant push in the years to come.

Prominent players operating within the global neurosurgery drugs market are Pfizer Inc., WOCKHARDT, Sun Pharmaceutical Industries Limited, and Mylan N.V.

Leave a Reply